1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. MAP3K
  4. MAP3K12/DLK/Pref-1 Isoform

MAP3K12/DLK/Pref-1

Mitogen-activated protein kinase kinase kinase 12 (MAP3K12, also known as Dual Leucine Zipper Kinase, DLK) is a serine/threonine kinase regulating neuronal development and axon regeneration[1][2][3]. DLK mediates stress-responsive signaling by activating the c-Jun N-terminal kinase (JNK) pathway, which in turn modulates apoptotic and regenerative transcriptional programs[4][5][6]. Mechanistically, DLK forms complexes with scaffolding proteins such as JIP1 to control JNK activation, and its activity is further modulated by palmitoylation, subcellular localization, and protein-protein interactions[3][7]. In disease models, DLK is upregulated in neurodegenerative conditions, Alzheimer's disease, and age-related hearing loss, promoting cell death via excessive autophagy and apoptosis[8][9][10]. In contrast, in postnatal pancreatic beta cells, DLK/JNK3 signaling enhances cell proliferation and metabolic adaptation, demonstrating context-dependent functionality[11][12]. Compared with the closely related isoform LZK, DLK activation triggers rapid degeneration in Purkinje neurons, while LZK induces slower degeneration, highlighting isoform-specific kinetics and cellular outcomes[5]. Small-molecule inhibitors of DLK, including ATP-competitive compounds and palmitoylation blockers, have shown efficacy in modulating neurodegenerative processes and injury-induced apoptosis in preclinical models[1][7][14]. Therefore, DLK serves as a versatile node in both injury-induced and developmental signaling, with potential for therapeutic targeting and experimental modulation.

References:

MAP3K12/DLK/Pref-1 Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-111277
    CEP-14513
    Inhibitor
    CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma.
  • HY-181662
    DLK-IN-2
    Inhibitor
    DLK-IN-2 is a selective inhibitor of DLK and neuroprotective agent. DLK-IN-2 shows no significant inhibition against CYPs 3A4, 2D6 and 2C9. DLK-IN-2 inhibits acute axonal palmitoylation of DLK, blocks DLK-dependent pro-degenerative axon-to-soma retrograde signaling and suppresses c-Jun phosphorylation. DLK-IN-2 can be used for the mechanistic study of neurodegenerative diseases.